From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Non-alcoholic liver disease (NAFLD) is now metabolic dysfunction-associated steatotic liver disease (MASLD), emphasizing the key metabolic factors of obesity, insulin resistance, vascular dysfunction and dyslipidaemia. Here, we discuss impacts on the existing body of clinical and preclinical liver disease research and on research moving forward.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationRobust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice
Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M., Ellis, E., Strom, S., Kay, M. A., Finegold, M., & Grompe, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1326 · Cited by 835
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Self-citationCan we use old NAFLD data under the new MASLD definition?
Song, S. J., Lai, J. C.-T., Wong, G. L.-H., Wong, V. W.-S., & Yip, T. C.-F. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.021 · Cited by 374
99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical
Hagström, H., Vessby, J., Ekstedt, M., & Shang, Y. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.026 · Cited by 372
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
The fecal mycobiome in non-alcoholic fatty liver disease
Demir, M., Lang, S., Hartmann, P., Duan, Y., Martin, A., Miyamoto, Y., Bondareva, M., Zhang, X., Wang, Y., Kasper, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.029 · Cited by 197
Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions
Kaffe, E., Roulis, M., Zhao, J., Qu, R., Sefik, E., Mirza, H., Zhou, J., Zheng, Y., Charkoftaki, G., Vasiliou, V., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.017 · Cited by 99
Cited by
Epidemiology of metabolic dysfunction-associated steatotic liver disease
Younossi, Z. M., Kalligeros, M., & Henry, L. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0431 · Cited by 960
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Self-citationExploring the Role of Extra Virgin Olive Oil (EVOO) in MASLD: Evidence from Human Consumption
Bernardino, M., Tiribelli, C., & Rosso, N. (2025) · Nutrients · doi:10.3390/nu17182932 · Cited by 7
Lee, S. E., Jo, M. G., Park, S. W., Kim, H. J., Yun, S. P., & Kim, J.-W. (2026) · Animal Cells and Systems · doi:10.1080/19768354.2026.2630463 · Cited by 2
“Metabolic dysfunction-associated steatotic liver disease (MASLD) has recently replaced the term nonalcoholic fatty liver disease to reflect the underlying metabolic risk factors and pathophysiological basis of the disease better (Hsu and Loomba 2024).”
Metadata
- Authors
- Hsu, C. L., & Loomba, R.
- Venue
- Nature Metabolism
- Published
- 2024-02-21
- Volume
- 6
- Issue
- 4
- Pages
- 600-602
- ISSN
- 2522-5812 (ISSN-L)
- OpenAlex
- W4391997845
- Cited by
- 123
- References
- 8
- FWCI
- 32.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.